Literature DB >> 20952439

The pathogenesis of idiopathic pulmonary fibrosis.

William R Coward1, Gauri Saini, Gisli Jenkins.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease with an appalling prognosis. The failure of anti-inflammatory therapies coupled with the observation that deranged epithelium overlies proliferative myofibroblasts to form the fibroblastic focus has lead to the emerging concept that IPF is a disease of deregulated epithelial-mesenchymal crosstalk. IPF is triggered by an as yet unidentified alveolar injury that leads to activation of transforming growth factor-β (TGF-β) and alveolar basement membrane disruption. In the presence of persisting injurious pathways, or disrupted repair pathways, activated TGF-β can lead to enhanced epithelial apoptosis and epithelial-to-mesenchymal transition (EMT) as well as fibroblast, and fibrocyte, transformation into myofibroblasts which are resistant to apoptosis. The resulting deposition of excess disrupted matrix by these myofibroblasts leads to the development of IPF.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20952439     DOI: 10.1177/1753465810379801

Source DB:  PubMed          Journal:  Ther Adv Respir Dis        ISSN: 1753-4658            Impact factor:   4.031


  112 in total

Review 1.  The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis.

Authors:  Rachel S Knipe; Andrew M Tager; James K Liao
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

2.  Genome-scale study of transcription factor expression in the branching mouse lung.

Authors:  John C Herriges; Lan Yi; Elizabeth A Hines; Julie F Harvey; Guoliang Xu; Paul A Gray; Qiufu Ma; Xin Sun
Journal:  Dev Dyn       Date:  2012-07-20       Impact factor: 3.780

Review 3.  Lung regeneration: a tale of mice and men.

Authors:  Maria C Basil; Edward E Morrisey
Journal:  Semin Cell Dev Biol       Date:  2019-11-21       Impact factor: 7.727

4.  Protective effect of dexpanthenol on bleomycin-induced pulmonary fibrosis in rats.

Authors:  Hilal Ermis; Hakan Parlakpinar; Gazi Gulbas; Nigar Vardi; Alaadin Polat; Asli Cetin; Talat Kilic; Zeynep Ayfer Aytemur
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-08-31       Impact factor: 3.000

5.  Plasminogen activator inhibitor-1 suppresses profibrotic responses in fibroblasts from fibrotic lungs.

Authors:  Amarnath S Marudamuthu; Shwetha K Shetty; Yashodhar P Bhandary; Sophia Karandashova; Michael Thompson; Venkatachalem Sathish; Galina Florova; Taryn B Hogan; Christina M Pabelick; Y S Prakash; Yoshikazu Tsukasaki; Jian Fu; Mitsuo Ikebe; Steven Idell; Sreerama Shetty
Journal:  J Biol Chem       Date:  2015-02-03       Impact factor: 5.157

6.  Angiotensin II: tapping the cell cycle machinery to kill endothelial cells.

Authors:  Michael A O'Reilly
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-08-10       Impact factor: 5.464

Review 7.  Role of the lysophospholipid mediators lysophosphatidic acid and sphingosine 1-phosphate in lung fibrosis.

Authors:  Barry S Shea; Andrew M Tager
Journal:  Proc Am Thorac Soc       Date:  2012-07

8.  Protective and therapeutic effect of molsidomine on bleomycin-induced lung fibrosis in rats.

Authors:  Talat Kilic; Hakan Parlakpinar; Alaadin Polat; Elif Taslidere; Nigar Vardi; Ediz Sarihan; Hilal Ermis; Kevser Tanbag
Journal:  Inflammation       Date:  2014-08       Impact factor: 4.092

9.  Neonatal hyperoxia increases sensitivity of adult mice to bleomycin-induced lung fibrosis.

Authors:  Min Yee; Bradley W Buczynski; B Paige Lawrence; Michael A O'Reilly
Journal:  Am J Respir Cell Mol Biol       Date:  2012-12-20       Impact factor: 6.914

10.  Fibrosis of two: Epithelial cell-fibroblast interactions in pulmonary fibrosis.

Authors:  Norihiko Sakai; Andrew M Tager
Journal:  Biochim Biophys Acta       Date:  2013-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.